Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey A Silverman

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Cancer Chemotherapy and Pharmacology|October 22, 2008
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor modelsUte Hoch, Jennifer Lynch, Yuji Sato, et al.
Clinical Pharmacology in Drug Development|October 13, 2017
The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy SubjectsYan Xin, Lixin Shao, Julie Maltzman, et al.
Clinical and Translational Science|December 5, 2020
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult VolunteersTong Lin, Martha Hernandez-Illas, Andres Rey, et al.
Clinical Pharmacology in Drug Development|July 26, 2021
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)Tong Lin, Todd Dumas, Josh Kaullen, et al.
Journal of Clinical Pharmacology|February 8, 2018
The Drug-Drug Interaction Profile of PresatovirYan Xin, Winnie Weng, Bernard P Murray, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivoCaroline D Scatena, Jeffrey L Kumer, Jennifer P Arbitrario, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinateVincent J Wacher, Jeffrey A Silverman, Susan Wong, et al.
Journal of Clinical Pharmacology|October 28, 2010
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver functionAgop Y Bedikian, Jeffrey A Silverman, Nicholas E Papadopoulos, et al.
Ebiomedicine|June 17, 2026
Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label studyHan Phan, Ben Barthel, Molly Madden, et al.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Cancer Chemotherapy and Pharmacology|October 22, 2008
Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor modelsUte Hoch, Jennifer Lynch, Yuji Sato, et al.
Clinical Pharmacology in Drug Development|October 13, 2017
The Relative Bioavailability, Food Effect, and Drug Interaction With Omeprazole of Momelotinib Tablet Formulation in Healthy SubjectsYan Xin, Lixin Shao, Julie Maltzman, et al.
Clinical and Translational Science|December 5, 2020
A Randomized Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Erwinia Asparaginase (JZP-458) in Healthy Adult VolunteersTong Lin, Martha Hernandez-Illas, Andres Rey, et al.
Clinical Pharmacology in Drug Development|July 26, 2021
Population Pharmacokinetic Model Development and Simulation for Recombinant Erwinia Asparaginase Produced in Pseudomonas fluorescens (JZP-458)Tong Lin, Todd Dumas, Josh Kaullen, et al.
Journal of Clinical Pharmacology|February 8, 2018
The Drug-Drug Interaction Profile of PresatovirYan Xin, Winnie Weng, Bernard P Murray, et al.
Cancer Chemotherapy and Pharmacology|January 9, 2010
Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivoCaroline D Scatena, Jeffrey L Kumer, Jennifer P Arbitrario, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 18, 2002
Sirolimus oral absorption in rats is increased by ketoconazole but is not affected by D-alpha-tocopheryl poly(ethylene glycol 1000) succinateVincent J Wacher, Jeffrey A Silverman, Susan Wong, et al.
Journal of Clinical Pharmacology|October 28, 2010
Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in cancer patients with impaired liver functionAgop Y Bedikian, Jeffrey A Silverman, Nicholas E Papadopoulos, et al.
Ebiomedicine|June 17, 2026
Effects of sevasemten (EDG-5506) on safety, biomarkers, and functional measures in adults with Becker muscular dystrophy: results of a phase 1b, open-label studyHan Phan, Ben Barthel, Molly Madden, et al.
Muscle & Nerve|June 2, 2025
A Phase 1, Double-Blind, Placebo-Controlled Trial of Sevasemten (EDG-5506), a Selective Modulator of Fast Skeletal Muscle Contraction, in Healthy Volunteers and Adults With Becker Muscular DystrophyJoanne Donovan, Jeffrey A Silverman, Ben Barthel, et al.
Pageof 4